Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA reviewers question benefits of Merck/Ariad, GSK sarcoma drugs

This article was originally published in Scrip

Executive Summary

With only small differences in median progression-free-survival (PFS) and overall survival between ridaforolimus, an experimental mTOR inhibitor under development by Merck and Ariad, and placebo, but particularly concerning adverse events of pneumonitis, infection and renal failure and impairment in study participants receiving the investigational drug, the US FDA wants its panel of outside advisers to weigh in on whether the product’s risk-benefit is favorable enough to approve the medicine as a maintenance therapy in patients with soft tissue and bone sarcomas.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts